SCYNEXIS (SCYX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
The annual meeting is scheduled for June 25, 2026, and will be held virtually, with six key proposals up for shareholder vote, including director elections, auditor ratification, executive compensation, equity plan amendments, and capital structure changes.
Shareholders can vote online, by phone, or by mail, and only those of record as of April 27, 2026, are eligible to vote.
The Board recommends voting in favor of all proposals and for annual say-on-pay votes.
Voting matters and shareholder proposals
Six proposals: election of six directors, ratification of Deloitte & Touche LLP as auditor, advisory vote on executive compensation, advisory vote on frequency of say-on-pay, amendment to increase shares under the 2024 Equity Incentive Plan, and amendment to increase authorized common stock.
Shareholders may submit proposals for the 2027 annual meeting by specified deadlines and must follow bylaw and SEC requirements.
Voting procedures and effects of abstentions and broker non-votes are detailed; a majority is required for most proposals.
Board of directors and corporate governance
Six nominees for director, with one current director retiring; board diversity is highlighted, with 43% women or racially/ethnically diverse.
Majority of directors are independent per Nasdaq standards; board committees include Audit, Compensation, and Nominating and Corporate Governance.
Board leadership is separated between Chairman and CEO; regular executive sessions are held by independent directors.
Stockholders can communicate directly with the board, and a Code of Business Conduct and Ethics is in place.
Latest events from SCYNEXIS
- Resale registration for 87M shares from a private placement; proceeds only from warrant exercises.SCYX
Registration filing1 May 2026 - Key votes include board elections, auditor ratification, and major share authorization changes.SCYX
Proxy filing1 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and capital increase.SCYX
Proxy filing30 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing27 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing17 Apr 2026 - Acquisition of SCY-770 for ADPKD offers major commercial potential and no royalty obligations.SCYX
M&A announcement2 Apr 2026 - SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026 - 2025 revenue rose sharply on GSK deals; SCY-247 clinical progress and cash runway extended.SCYX
Q4 20254 Mar 2026 - Advancing next-gen antifungal SCY-247 and expanding GSK partnership, with strong financials.SCYX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026